Skip to content
Open access

Sex-difference in cardiovascular outcomes following achieved LDL-C Levels <1.0 mmol/L in patients with coronary artery disease

Oct 2026 · European Heart Journal · 0 citations

Abstract

Women with cardiovascular disease still continue to present substantially higher mortality than men, which highlights the need for appropriate anti-atherosclerotic management. Current ESC/EAS guidelines advocate achieving stricter LDL-C goals (<1.0 and 1.4 mmol/L) for the secondary prevention of ASCVD in very high-risk and extreme risk patients, respectively. However, in recent randomized controlled trials including very high-risk patients, potent agents lowered LDL-C by around 0.5–0.7 mmol/L, and reduced risks of subsequent ASCVD. These observations lead to the hypothesis that men and women with CAD may more benefit from the control of LDL-C <1.0 mmol/L rather than ESC guideline-recommended LDL-C goal (<1.4 mmol/L). To investigate cardiovascular outcomes following achieved LDL-C levels <1.0 mmol/L in men and women with CAD. The current study was a multi-center, retrospective analysis of 2,560 patients with CAD receiving PCI at 3 sites (men/women=1,882/678). Achieved LDL-C level was defined as measured LDL-C levels at 2 months after PCI. Clinical demographics and cardiovascular outcomes (MACE=cardiac death + non-fatal MI + clinically-driven coronary revascularization at non-culprit segment) were compared in men and women stratified according to achieved LDL-C levels (<1.0, 1.0-1.4 and ≥1.4 mmol/L), respectively. The proportion of achieved LDL-C <1.0 mmol/L was significantly lower in women compared to men (6.0 vs. 10.4%, p=0.001). Men with achieved LDL-C levels <1.0 mmol/L were less likely to exhibit dyslipidemia (p<0.001) (Table). Furthermore, more intensified lipid-lowering agents (statin: p<0.001, ezetimibe: p<0.001, PCSK9-I: p<0.001) were used in those with LDL-C<1.0 mmol/L (Table). During the 2.5-year observational period, men with achieved LDL-C <1.0 mmol/l was associated with a lower likelihood of experiencing MACE (Figure, log-rank p<0.001). In women who achieved LDL-C levels <1.0 mol/L, in addition to a lower frequency of dyslipidemia (p=0.004), greater frequencies of hypertension (p=0.018) and type 2 diabetes mellitus (p=0.047) were observed (Table). As expected, they more frequently received statin (p=0.041) and PCSK9 inhibitor (p=<0.001) (Table). Similar to men, mitigating risks of MACE was observed in women who achieved LDL-C levels <1.0 mmol/L (Figure, log-rank p=0.027). There was no significant interaction about the efficacy of LDL-C levels <1.0 mmol/L on the occurrence of MACE between men and women (p-interaction=0.691). In women with CAD, only 6.0% of them achieved LDL-C levels <1.0 mmol/L. Achieved LDL-C levels <1.0 mmol/L provided cardiovascular benefits in both men and women with CAD. These observations support LDL-C <1.0 mmol/L as a therapeutic goal in women with CAD to further mitigate risks of subsequent ASCVD. The adoption of a more stringent LDL-C goal may be clinically needed to optimize cardiovascular outcomes in not only men but women with CAD.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.